UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions

Cancer prevention research (Philadelphia, Pa.), 2009-10, Vol.2 (10), p.868-878

2009

Volltextzugriff (PDF)

Sex, Age, and Race Effects on Immunogenicity of MenB-FHbp, A Bivalent Meningococcal B Vaccine: Pooled Evaluation of Clinical Trial Data

Infectious diseases and therapy, 2020-09, Vol.9 (3), p.625-639

2020

Volltextzugriff (PDF)

MenB-FHbp Vaccine Protects Against Diverse Meningococcal Strains in Adolescents and Young Adults: Post Hoc Analysis of Two Phase 3 Studies

Infectious diseases and therapy, 2020-09, Vol.9 (3), p.641-656

2020

Volltextzugriff (PDF)

Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial

The Lancet infectious diseases, 2023-12, Vol.23 (12), p.1370-1382

2023

Volltextzugriff (PDF)

A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults

The New England journal of medicine, 2017-12, Vol.377 (24), p.2349-2362

2017

Volltextzugriff (PDF)

A phase 3 study to assess the immunogenicity, safety, and tolerability of MenB-FHbp administered as a 2-dose schedule in adolescents and young adults

Vaccine, 2022-01, Vol.40 (2), p.351-358

2022

Volltextzugriff (PDF)

1638. Development of a Model to Estimate Persistence of hSBA Titers Over Time Following a Primary Series and Booster Dose of the Pentavalent Meningococcal MenABCWY Vaccine

Open forum infectious diseases, 2023-11, Vol.10 (Supplement_2)

2023

Volltextzugriff (PDF)

Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months

Vaccine, 2021-07, Vol.39 (32), p.4545-4554

2021

Volltextzugriff (PDF)

Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial

BMJ, 2010-07, Vol.341 (7766), p.c3493-c3493

International edition, 2010

Volltextzugriff (PDF)

Clinical data supporting a 2-dose schedule of MenB-FHbp, a bivalent meningococcal serogroup B vaccine, in adolescents and young adults

Vaccine, 2018-06, Vol.36 (28), p.4004-4013

2018

Volltextzugriff (PDF)

Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents

Vaccine, 2019-03, Vol.37 (12), p.1710-1719

2019

Volltextzugriff (PDF)

6. Pentavalent Meningococcal (MenABCWY) Vaccine is Safe and Well Tolerated With Immunogenicity Noninferior to Coadministered MenB-FHbp and MenACWY-CRM in a Phase 2 Study of Healthy Adolescents and Young Adults

Open forum infectious diseases, 2020-12, Vol.7 (Supplement_1), p.S25-S26

2020

Volltextzugriff (PDF)

2722. Effects of Sex, Age, and Race on Immunogenicity of MenB-FHbp, a Bivalent Meningococcal B Vaccine: A Pooled Evaluation of Clinical Trial Data

Open forum infectious diseases, 2019-10, Vol.6 (Supplement_2), p.S958-S958

2019

Volltextzugriff (PDF)

Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – A combined analysis of five phase III clinical trials

Papillomavirus research, 2017-06, Vol.3, p.105-115

2017

Volltextzugriff (PDF)

Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine

Human vaccines & immunotherapeutics, 2015-06, Vol.11 (6), p.1313-1322

2015

Volltextzugriff (PDF)

Immunogenicity of MenB-FHbp (Bivalent rLP2086), a Meningococcal Serogroup B Vaccine, in US Adolescents: Results From a Phase 3 Trial

Open forum infectious diseases, 2016-12, Vol.3 (suppl_1)

2016

Volltextzugriff (PDF)

Modeling excess zeroes in an integrated analysis of vaccine safety

Human Vaccines & Immunotherapeutics, 2018, Vol.14 (6), p.1530-1533

2018

Volltextzugriff (PDF)

DNAfusion: an R/Bioconductor package for increased sensitivity of detecting gene fusions in liquid biopsies

BMC bioinformatics, 2023-04, Vol.24 (1), p.131-131, Article 131

2023

Volltextzugriff (PDF)

Progression to Myelofibrosis in Patients with Essential Thrombocythemia: A Real-World Analysis from the Prospective MOST Study

Blood, 2023-11, Vol.142 (Supplement 1), p.2433-2433

2023

Volltextzugriff (PDF)

MPN-087 Progression to Myelofibrosis (MF) in Patients With Essential Thrombocythemia (ET): An Analysis From the Prospective Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S410-S411

2024

Volltextzugriff (PDF)

Progression to Myelofibrosis (MF) in Patients With Essential Thrombocythemia (ET): An Analysis From the Prospective Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S198-S198

2024

Volltextzugriff (PDF)

Abstract 2082: DNAfusion: An R/Bioconductor package for increased sensitivity of detecting EML4-ALK gene fusions in liquid biopsies from cancer patients

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.2082-2082

2023

Volltextzugriff (PDF)

Moose browsing and forage availability: a scale-dependent relationship?

Canadian journal of zoology, 2007-03, Vol.85 (3), p.372-380

2007

Volltextzugriff (PDF)

1 – 25 von 29

Suche als RSS-Feed

Aktive Filter

ThemaChild

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(28)
Berichte
(1)

Sprache

Englisch
(29)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions

Sex, Age, and Race Effects on Immunogenicity of MenB-FHbp, A Bivalent Meningococcal B Vaccine: Pooled Evaluation of Clinical Trial Data

MenB-FHbp Vaccine Protects Against Diverse Meningococcal Strains in Adolescents and Young Adults: Post Hoc Analysis of Two Phase 3 Studies

Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial

A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults

A phase 3 study to assess the immunogenicity, safety, and tolerability of MenB-FHbp administered as a 2-dose schedule in adolescents and young adults

1638. Development of a Model to Estimate Persistence of hSBA Titers Over Time Following a Primary Series and Booster Dose of the Pentavalent Meningococcal MenABCWY Vaccine

Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months

Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial

Clinical data supporting a 2-dose schedule of MenB-FHbp, a bivalent meningococcal serogroup B vaccine, in adolescents and young adults

Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents

6. Pentavalent Meningococcal (MenABCWY) Vaccine is Safe and Well Tolerated With Immunogenicity Noninferior to Coadministered MenB-FHbp and MenACWY-CRM in a Phase 2 Study of Healthy Adolescents and Young Adults

2722. Effects of Sex, Age, and Race on Immunogenicity of MenB-FHbp, a Bivalent Meningococcal B Vaccine: A Pooled Evaluation of Clinical Trial Data

Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – A combined analysis of five phase III clinical trials

Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection

Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine

Immunogenicity of MenB-FHbp (Bivalent rLP2086), a Meningococcal Serogroup B Vaccine, in US Adolescents: Results From a Phase 3 Trial

Modeling excess zeroes in an integrated analysis of vaccine safety

A Phase 2 Study of the Immunogenicity, Safety, and Tolerability of MenB-FHbp, a Bivalent Meningococcal B Vaccine, in Healthy Toddlers

DNAfusion: an R/Bioconductor package for increased sensitivity of detecting gene fusions in liquid biopsies

Progression to Myelofibrosis in Patients with Essential Thrombocythemia: A Real-World Analysis from the Prospective MOST Study

MPN-087 Progression to Myelofibrosis (MF) in Patients With Essential Thrombocythemia (ET): An Analysis From the Prospective Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)

Progression to Myelofibrosis (MF) in Patients With Essential Thrombocythemia (ET): An Analysis From the Prospective Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)

Abstract 2082: DNAfusion: An R/Bioconductor package for increased sensitivity of detecting EML4-ALK gene fusions in liquid biopsies from cancer patients

Moose browsing and forage availability: a scale-dependent relationship?

Aktive Filter

Suchergebnisse filtern